Allumiqs and Prolytix Collbaorate to Develop Drug Discovery Solutions

Allumiqs, an Omics solutions provider, and Prolytix, a protein chemistry specialist firm, have collaborated to streamline the drug development process.  

The two organisations are passionate about partnering to provide their customers with bikoanalytical solutions to move their drug candidates forward, starting from the initial stages of research and development all the way to getting approval for production batches.  

Allumiqs will input biological insights and therapeutic profiling during the initial phases of a customer’s research and development endeavors, prior to Prolytix providing a tailored approach for assessments of stability, and Good Manufacturing Practice clearance testing.  

Allumiqs’ head executive, Kent MacLean, stated, “We found many synergies in working with the team at Prolytix in collaborative customer projects, most importantly our shared commitment to customer success.”  

MacLean went on to add, “Our goal is to make it simple for our customers to engage with the innovation partners they need at every stage of the drug discovery process, and our partnership with Prolytix does that. 

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.